Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-01-13

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Buprenorphine and naloxone from Actavis Pharma, Inc., authorizing changes to the approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)